Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer.

Oncogene - 1 Aug 2021

Clements Miranda E, Holtslander Lauren, Edwards Courtney, Todd Vera, Dooyema Samuel D R, Bullock Kennady, Bergdorf Kensey, Zahnow Cynthia A, Connolly Roisin M, Johnson Rachelle W

Abstract excerpt

Despite advances in breast cancer treatment, residual disease driven by dormant tumor cells continues to be a significant clinical problem. Leukemia inhibitory factor receptor (LIFR) promotes a dormancy phenotype in breast cancer cells and LIFR loss is correlated with poor patient survival. Herein, we demonstrate that histone deacetylase inhibitors (HDACi), which are in phase III clinical trials for breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Epigenesis, Genetic

Share to Gene Expression Regulation, Neoplastic

Share to Histone Deacetylase Inhibitors

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 34247191
DOI: 10.1038/s41388-021-01931-1
PMCID: PMC8403155

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer.PMID 34247191Read ↗

Dormancy Signatures and Metastasis in Estrogen Receptor Positive and Negative Breast CancerSemantic proximity Read ↗

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumoursSemantic proximity Read ↗

Controversies in clinical cancer dormancySemantic proximity Read ↗

Dormancy in breast cancerSemantic proximity Read ↗

Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implicationsSemantic proximity Read ↗

Cancer cell dormancy: An update to 2025Semantic proximity Read ↗

Decoding the adaptive survival mechanisms of breast cancer dormancySemantic proximity Read ↗

Gene expression predicts dormant metastatic breast cancer cell phenotype.Semantic proximity Read ↗

NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell ProliferationSemantic proximity Read ↗

Unveiling the role of cellular dormancy in cancer progression and recurrenceSemantic proximity Read ↗

Cellular dormancy in minimal residual disease following targeted therapySemantic proximity Read ↗

The CXCL10/CXCR3 axis is essential for sustaining immunological dormancy in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.